Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

CytomX Therapeutics (6C1) Drug Pipeline

Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Pembrolizumab, Keytruda, Cx-801Solid Tumor, AdultPhase IRecruitingFirst In Human Study of CX-801 in Advanced Solid TumorsJun 12, 2024―
Cx-2051Solid Tumor, AdultPhase IRecruitingFirst In Human Study of CX-2051 in Advanced Solid TumorsFeb 12, 2024
Cx-904Solid TumorsPhase ITerminatedA Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid TumorsMay 19, 2022―
Ipilimumab, Cx-072Solid Tumor, Unresectable Or Metastatic MelanomaPhase IITerminatedPROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid TumorsMay 14, 2019―
Ipilimumab, Vemurafenib, Cx-072Solid Tumor, Lymphomaphase1AndPhase2TerminatedPROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or LymphomasDec 26, 2016―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does CytomX Therapeutics Inc. (CH:6C1) have in its pipeline
CytomX Therapeutics CH:6C1 is currently developing the following drugs: Pembrolizumab, Keytruda, Cx-801, Cx-2051, Cx-904, Ipilimumab, Cx-072, Ipilimumab, Vemurafenib, Cx-072. These drug candidates are in various stages of clinical development as the company works toward FDA approval.